{"id":"rebif-new-formulation-rnf","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Flu-like symptoms"},{"rate":"30-50%","effect":"Injection site reactions"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Headache"},{"rate":"10-30%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by reducing inflammation in the central nervous system, which helps to slow the progression of the disease. Interferon beta-1a is a protein that helps to regulate the immune system and reduce the severity of MS symptoms. By reducing inflammation, Rebif RNF can help to slow the progression of disability and reduce the frequency of relapses.","oneSentence":"Rebif new formulation (RNF) is an interferon beta-1a used to treat multiple sclerosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:17.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT00725985","phase":"PHASE3","title":"Oral Cladribine in Early Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2008-12-31","conditions":"Multiple Sclerosis","enrollment":617},{"nctId":"NCT00436826","phase":"PHASE2","title":"A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2006-11-30","conditions":"Multiple Sclerosis","enrollment":172},{"nctId":"NCT00813709","phase":"PHASE3","title":"Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-12","conditions":"Multiple Sclerosis, Clinically Isolated Syndrome","enrollment":402},{"nctId":"NCT00110396","phase":"PHASE3","title":"Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2005-01","conditions":"Multiple Sclerosis","enrollment":260},{"nctId":"NCT00441103","phase":"PHASE3","title":"A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2006-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":180},{"nctId":"NCT00735007","phase":"PHASE3","title":"12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2008-07","conditions":"Multiple Sclerosis","enrollment":106},{"nctId":"NCT00428584","phase":"PHASE3","title":"RNF and Betaseron® Tolerability Study","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2006-12","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":129},{"nctId":"NCT00472797","phase":"PHASE3","title":"Rebif New Formulation (RNF) Quality of Life (QOL) Study","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2007-04","conditions":"Relapsing Multiple Sclerosis","enrollment":232}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rebif® new formulation (RNF)","genericName":"Rebif® new formulation (RNF)","companyName":"EMD Serono Research & Development Institute, Inc.","companyId":"emd-serono-research-development-institute-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rebif's new formulation (RNF) is a human interferon beta-1a used to treat Relapsing Remitting Multiple Sclerosis (RRMS) and Multiple Sclerosis. The new formulation is also free from human serum albumin (HSA) and fetal bovine serum (FBS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}